While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

The article " After a Reset Year, Is Moderna Stock Poised for a Comeback? " first appeared on MarketBeat.

The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...